Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Inflammation is a hallmark of cancer(1). In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities(2–5). Whether myeloid inflammation drives...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Christina, Sharp, Adam, Gurel, Bora, Crespo, Mateus, Figueiredo, Ines, Jain, Suneil, Vogl, Ursula, Rekowski, Jan, Rouhifard, Mahtab, Gallagher, Lewis, Yuan, Wei, Carreira, Suzanne, Chandran, Khobe, Paschalis, Alec, Colombo, Ilaria, Stathis, Anastasios, Bertan, Claudia, Seed, George, Goodall, Jane, Raynaud, Florence, Ruddle, Ruth, Swales, Karen E., Malia, Jason, Bogdan, Denisa, Tiu, Crescens, Caldwell, Reece, Aversa, Caterina, Ferreira, Ana, Neeb, Antje, Tunariu, Nina, Westaby, Daniel, Carmichael, Juliet, Fenor de la Maza, Maria Dolores, Yap, Christina, Matthews, Ruth, Badham, Hannah, Prout, Toby, Turner, Alison, Parmar, Mona, Tovey, Holly, Riisnaes, Ruth, Flohr, Penny, Gil, Jesus, Waugh, David, Decordova, Shaun, Schlag, Anna, Calì, Bianca, Alimonti, Andrea, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686834/
https://www.ncbi.nlm.nih.gov/pubmed/37844613
http://dx.doi.org/10.1038/s41586-023-06696-z

Ejemplares similares

Ejemplares similares